Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BLLN vs ADPT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BLLN Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 9–1 Matrix Metrics)

BLLN Overall Winner 6-Pillar Tally: BLLN 4 – 2 ADPT Matrix Metrics: BLLN 9 – 1 ADPT

As of Nov 16, 2026, BillionToOne, Inc. (BLLN) is the stronger overall head-to-head candidate over Adaptive Biotechnologies Corporation (ADPT) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BLLN carries a Unified Composite Score of 45.8/100 (HOLD) at $96.31 (61.3x Forward P/E, 10.2% operating margin), whereas ADPT carries 43.8/100 (HOLD) at $27.87 (N/M Forward P/E, -16.2% operating margin).

  • Technical & Structure Timing Caution: BLLN is currently in a Breakdown options structure phase (RSI 34.4); meanwhile ADPT trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BLLN vs ADPT
BLLN US Equity Head-to-Head Winner
BillionToOne, Inc.
Services-Medical Laboratories
$96.31
-8.41% 1D
Market Cap $5.0B
TTM Revenue $437M
Forward P/E 61.3x
Beta / 30D Vol 1.44β · 42% Vol
Unified Composite Score
45.8 / 100 HOLD
Tech 27.0 Fund 53.0 Flow 71.0 Mom 70.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 34
RSI-14: 34.4 · SMA20: $109.99 · SMA50: $106.93
ADPT NASDAQ
Adaptive Biotechnologies Corporation Common Stock
Biological Products, (No Disgnostic Substances)
$27.87
-4.03% 1D
Market Cap $4.7B
TTM Revenue $298M
Forward P/E N/M
Beta / 30D Vol 1.74β · 60% Vol
Unified Composite Score
43.8 / 100 HOLD
Tech 15.0 Fund 43.0 Flow 69.0 Mom 54.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.2% over 20 days), RSI 52
RSI-14: 51.8 · SMA20: $27.26 · SMA50: $26.98

6-Pillar Scorecard Institutional Category Breakdown (BLLN 4 – 2 ADPT)

Columns: Metric · BLLN · ADPT
1. Valuation Multiples BLLN
Forward P/E 61.3x N/M
Trailing P/E 114.3x N/M
PEG Ratio N/M N/M
EV / Revenue 10.5x 16.9x
2. Growth & Scale BLLN
Revenue Growth (YoY) +47.2% -10.7%
Earnings Growth (YoY) +220.0% -70.1%
TTM Revenue (USD) $437M $298M
Market Cap $5.0B $4.7B
3. Profitability & Quality BLLN
Gross Margin 71.4% 46.2%
Operating Margin 10.2% -16.2%
Net Profit Margin 10.5% -23.7%
Return on Equity (ROE) 13.2% -36.4%
4. Balance Sheet & Cash Flow BLLN
Cash Generation (TTM) $34M -$8.8M
Cash Flow Margin 7.8% -3.0%
Net Cash / Leverage $421M Net Cash $333M Net Debt (2.32x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ADPT
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 113.8% (26th %ile) 78.0% (36th %ile)
Put/Call OI Skew 1.21x (Put-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral ACCUMULATION · Markup
6. R&D & Supply-Chain Moat ADPT
OpEx & R&D Intensity 61.2% of Rev ($267M) 62.4% of Rev ($186M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BLLN (9) vs ADPT (1)
Institutional Metric BLLN ADPT Criterion Row Edge
Market Capitalization
Scale
$5.0B $4.7B Larger Scale BLLN
Trailing P/E Ratio
Valuation
114.3x N/M Lower Multiple BLLN
Forward P/E Ratio
Valuation
61.3x N/M Lower Multiple BLLN
Revenue Growth (YoY)
Growth
+47.2% -10.7% Higher Growth BLLN
Operating Margin (TTM)
Profitability
10.2% -16.2% Higher Margin BLLN
Net Profit Margin
Profitability
10.5% -23.7% Higher Margin BLLN
Return on Equity (ROE)
Capital Efficiency
13.2% -36.4% Higher ROE BLLN
52-Week Range Position
Momentum
39% ($62–$150) 78% ($12–$32) Stronger Trend ADPT
Beta / 30D Volatility
Risk Regime
1.44β · 42% Vol 1.74β · 60% Vol Lower Realized Risk BLLN
Unified Institutional Score
Composite Signal
45.8 / 100 (HOLD) 43.8 / 100 (HOLD) Higher Composite BLLN
Trailing 12M Revenue (USD)
Operating Scale
$437M $298M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
71.4% 46.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 10.5x EV/Rev N/M PEG · 16.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$34M ($421M Net Cash) -$8.8M ($333M Net Debt (2.32x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ADPT +17.87 pp
BLLN: -1.84% · ADPT: +16.03%
3M Horizon ADPT +4.02 pp
BLLN: +9.46% · ADPT: +13.48%
6M Horizon ADPT +107.45 pp
BLLN: +11.83% · ADPT: +119.28%
1Y Horizon ADPT +89.55 pp
BLLN: +7.55% · ADPT: +97.1%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period BLLN Revenue ADPT Revenue BLLN Op. Margin ADPT Op. Margin Margin Leader
FY2018 N/A $60M N/A -89.4% ADPT
FY2019 N/A $90M N/A -92.1% ADPT
FY2020 N/A $100M N/A -155.3% ADPT
FY2021 N/A $150M N/A -135.4% ADPT
FY2022 N/A $190M N/A -108.0% ADPT
FY2023 $70M $170M -96.9% -133.3% BLLN
FY2024 $150M $180M -30.9% -90.8% BLLN
FY2025 $310M $280M 5.3% -20.6% BLLN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BLLN BREAKDOWN
78d in phase · OBV DISTRIBUTION
Current IV 113.8%
IV Percentile 26th %ile
Put/Call OI Skew 1.21x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact BLLN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ADPT CONSOLIDATION
69d in phase · OBV ACCUMULATION
Current IV 78.0%
IV Percentile 36th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ADPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BLLN Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $5.0B market capitalization and 10.2% operating margin.
OpEx & R&D Reinvestment 61.2% of Rev ($267M)
90D Engineering Disclosures 0 Published
ADPT Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $4.7B market capitalization and -16.2% operating margin.
OpEx & R&D Reinvestment 62.4% of Rev ($186M)
90D Engineering Disclosures 0 Published

Investor FAQ BLLN vs ADPT Key Questions & Quantitative Answers

As of Nov 16, 2026, BillionToOne, Inc. (BLLN) is the stronger overall head-to-head candidate over Adaptive Biotechnologies Corporation (ADPT) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BLLN carries a Unified Composite Score of 45.8/100 (HOLD) at $96.31 (61.3x Forward P/E, 10.2% operating margin), whereas ADPT carries 43.8/100 (HOLD) at $27.87 (N/M Forward P/E, -16.2% operating margin). Technical & Structure Timing Caution: BLLN is currently in a Breakdown options structure phase (RSI 34.4); meanwhile ADPT trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BLLN leads the Growth & Scale pillar: BLLN posts +47.2% YoY revenue growth and +220.0% YoY earnings growth on $437M TTM revenue (71.4% gross margin, 10.2% operating margin), compared with ADPT at -10.7% YoY revenue growth and -70.1% YoY earnings growth on $298M TTM revenue (46.2% gross margin, -16.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), BLLN cumulative revenue shifted +342.9% while ADPT shifted +366.7%. In operating R&D and SG&A reinvestment, BLLN deploys 61.2% of Rev ($267M) (0 90-day corporate R&D disclosures) versus 62.4% of Rev ($186M) (0 disclosures) for ADPT.

BLLN screens cheaper on headline valuation multiples. BLLN trades at 61.3x Forward P/E, 114.3x Trailing P/E, N/M PEG, and 10.5x EV/Revenue (7.8% FCF margin), whereas ADPT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 16.9x EV/Revenue (-3.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BLLN (13.2% ROE) versus ADPT (-36.4% ROE) capital efficiency.

In options market volatility and institutional positioning, BLLN carries 113.8% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 1.21x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.44β · 42% Vol realized risk). By comparison, ADPT carries 78.0% implied volatility (36th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.74β · 60% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.